Market Herald logo


Be the first with the news that moves the market

Melbourne based therapeutic antibody development group, Patrys Limited, has updated the market on a range of new activities being pursued. 

Previously stated in October 2018, an international service provider for the development of PAT-DX1 had been selected. This partnership will advance the clinic as a stable cell line, which is a critical component for the development of the pathway for therapeutic antibodies. 

PAT-DSX1 could potentially be used for the treatment of a broad range of cancers with impaired DNA damage repair, most likely for glioblastoma, cancer affecting the brain or spine, and triple negative breast cancer. 

Patrys Limited hopes to announce the results from two studies conducted at the beginning of the year. The first experiment is still ongoing and the results for the second will not be released until the first experiment is completed. 

Patrys Limited has received several grants from various Australian Government departments resulting around $35,000. These funds are to be used for the upcoming formulation around PAT-DX1 and other antibodies. 

Please find announcement attached:

PAB by the numbers
More From The Market Herald

" Kleos Space (ASX:KSS) completes $10m debt facility with PURE Asset Management

Kleos Space (ASX:KSS) has completed its $10 million secured debt facility with PURE Asset management to…
The Market Herald Video

" Cynata Therapeutics (ASX:CYP) to conclude MEND trial following strategic review

Cynata Therapeutics (ASX:CYP) has completed a strategic review of its clinical development pipeline to maximise commercial…
The Market Herald Video

" AVITA Medical (ASX:AVH) reports positive results from soft tissue trial

AVITA Medical (ASX:AVH) reports positive top line results for its RECELL trial in patients with soft-tissue…

" Eden Innovation (ASX:EDE) completes US secured debt restructure

Eden Innovation (ASX:EDE) has completed refinancing of the two existing secured loans in the US.